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A malaria vaccine for mass immuniza-
tion, which could be delivered cheaply and
widely and provide long lasting protection,
would have a massive effect on global
public health. However, such a vaccine
does not currently exist. The reduction in
global malaria incidence, in part due to
the ongoing introduction of mosquito
control measures such as insecticide-treat-
ed nets and disease treatment with arte-
mesinin combination drug therapy, raises
the performance requirements for a future
vaccine, since the cost may be high relative
to that of other interventions and the scale
of the disease burden. Nevertheless, histo-
ry teaches that complacency and an over-
reliance on a small number of tools to
combat this disease are dangerous. There
is therefore still a pressing need for a
vaccine to complement other control and
potential elimination tools. The big ques-
tion is whether or not a malaria vaccine
that fulfills the above criteria can be
developed.
RTS,S, the first malaria vaccine that
targets the so-called pre-erythrocytic stages
in humans, has just started in Phase 3 trials
[1]; this is a major achievement based on
numerous trials (most recent trials in [2,3])
and 40 years of research (reviewed in [4]).
Although questions persist about whether
this vaccine will be effective enough [5]
and about the nature of the protective
mechanisms, does this achievement signal
the end for research on new vaccines and
the basic parasite biology and host immu-
nology that underpins vaccine research?
Other malaria vaccine candidates that
target the asexual blood stages are not so
advanced, and without improvement may
not live up to hopes and expectations
[6,7]; is it therefore time to reassess the
strategy on which they were developed
[8]? For example, instead of subunit or
vectored vaccines, the potential use of live
or live and attenuated parasite vaccines
has been proposed [9,10] and is being
pursued (http://www.sanaria.com/). Now
that the international community is striv-
ing to eliminate malaria, maybe the
requirements for a malaria vaccine are
changing. Perhaps now is the time for a
greater effort to research and develop the
next generation of malaria vaccines. If this
is the time for reinvigoration, what more
do we need to know to develop malaria
vaccines?
Current vaccines are based on a handful
of proteins, several of which were first
described several decades ago and before
analysis of the Plasmodium falciparum ge-
nome indicated that there are about 5,400
protein-coding genes, some of which are
expressed in an exquisitely stage-specific
manner and others that are not. Are any
of these other proteins antigens that are
worth considering for vaccine develop-
ment? It is unlikely that the level of
resources devoted to the circumsporozoite
surface protein (CSP) development that
led to RTS,S could be mustered to support
the further development of any new
antigen. If all new malaria vaccines need
to be compared against RTS,S, this could
only be done in an expensive clinical trial
format since alternative assays of efficacy
do not exist. The cost and practicalities of
this may inhibit vaccine-related research
and the development of next generation
vaccines, because a company or public–
private partnership may not be prepared
to put in the resources to produce a new
vaccine. We must, therefore, ask where
limited resources are best placed; vaccine
discovery and development are both
expensive. We have to take rational
approaches; it’s the best we can do, and
resources are not available for purely
empirical approaches. We need to en-
hance efforts on basic science in combi-
nation with clinical studies to provide a
strong rationale for further vaccine devel-
opment. This will need to be an integrated
rather than a compartmentalized ap-
proach; vaccine development from antigen
discovery to clinical trial is not a linear
process. For example, clinical samples
collected as part of a vaccine evaluation
trial are essential for the development of
better and more appropriate methods and
assays to understand relevant human
immune responses.
Naturally Acquired Immunity—
Do We Need to Do Better with a
Vaccine?
The malaria parasite has co-evolved
with its host over tens of thousands of
years, so it is no surprise that it has a
variety of mechanisms to evade the host
immune response. P. falciparum also has a
complex life cycle, and even now we are
discovering new aspects of its biology. For
a malaria vaccine, the big strategic ques-
tions remain: which stage or stages of the
life cycle do we want to target, what are
the targets, and how do we deliver them?
Can a malaria vaccine mature the im-
mune system from that of a naı ¨ve
individual to that of an individual protect-
ed from death and disease? Can we do
better than what is achieved in naturally
acquired immunity? An increased focus on
elimination of malaria has led to the
suggestion that a transmission-blocking
vaccine, either targeting sexual stages
alone or sexual- and pre-erythrocytic
stages, is all we will need in the future;
this is optimistic because of the apparent
lack of naturally acquired immunity to
these stages and the potential lack of
benefit to the individual vaccinee.
With time and exposure, individuals
that survive a malaria infection develop
immunity to the disease. The acquisition
of immunity that protects against death
and severe disease precedes that which
protects against mild malaria [11]. Sterile
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may not have consequences for the
individual, but it is important for prevent-
ing transmission and eventually eliminat-
ing the parasite. Different strategies tar-
geting different stages of the life cycle and
the use of attenuated parasites or mixtures
of several or single antigens in a variety of
live, attenuated vector- or adjuvant-based
delivery systems are all being investigated.
This is the basis upon which the develop-
ment of a malaria vaccine rests. Since in
holoendemic areas it is young children
rather than adults who are particularly at
risk, we need a better understanding of the
maturation of the immune system with
age. This, together with immunological
memory, is one area for immunologists to
make significant contributions to the
malaria field [12].
Different Facets of Immunity
Effective protection involves both cellu-
lar and humoral immunity, with antibody
being important in targeting free parasites
and the blood stages, and a cellular
response probably most important against
pre-erythrocytic stages. However, the tar-
gets and the mechanisms still need further
elucidation. Studies of immunity induced
by experimental infection of humans will
provide considerable insight into mecha-
nisms of immunity and their targets [13].
The antigens are many and varied and
most remain to be characterised. Some
proteins undergo antigenic variation, oth-
ers are highly polymorphic, and some are
conserved in sequence. Antigenic variation
has been described largely in the context
of proteins on the infected red cell surface
[14], but is also a feature of merozoite
proteins involved in invasion and coded by
small gene families [15]. Extensive se-
quence polymorphism is a feature of
merozoite proteins such as merozoite
surface protein 2 (MSP2) [16] and apical
membrane antigen (AMA)1 [17], whereas
parts of MSP1 seem to be highly con-
served and yet also the target of protective
antibodies [18]. We still don’t know for
certain whether immunity requires accu-
mulation of responses to different forms of
variant or diverse antigens, additive re-
sponses to a number of antigens [19], or
the right response against a single antigen
(for example, in terms of fine specificity,
avidity, concentration, and class of anti-
body) [18]. If antigenic diversity is the
primary driver of immune evasion, it may
never be possible to develop a sufficiently
complex vaccine. Whatever the delivery
system used, the repertoire of antigens will
be limited, so perhaps we need to focus on
first establishing the feasibility of vaccina-
tion against a heterogeneous population of
parasites. Using massively parallel se-
quencing technologies to survey the ge-
nome and transcriptome of wild parasites,
and methods to measure the specificity
and level of immune responses to many
individual antigens [20] in single individ-
uals of well-defined clinical status, together
with informatics tools to analyse the data
[21], will provide insights into this issue.
A Focus on Merozoites
It has been proposed that acquisition of
immunity to strain-transcending epitopes
is a feature of natural infection [11]. If
antigenic variation is therefore not of
major significance in acquisition of immu-
nity, then proteins on the surface of the
infected red cell such as EMP1, rifins, and
stevors may have little importance as
vaccine candidates for the asexual blood
stages. The focus is placed on the
merozoite, in particular on proteins that
are exposed to antibodies such as those on
the surface, in the micronemes/rhoptries,
and in the parasitophorous vacuole, in-
cluding shed and soluble proteins. The
duration of a protein’s accessibility to
antibody is an important criterion and
may explain why the parasite sheds all or
most of its surface proteins at invasion.
Removal of immune complexes from the
parasite surface will reduce susceptibility
to Fc-mediated effector functions.
Mostvaccinescurrentlyinorapproaching
clinical testing are based on antigens that
were first described almost 30 years ago. It
was first shown in 1981 that immunisation
with a single protein (MSP1) protected
against challenge infection in a rodent
malaria model [22]. The genome/transcrip-
tome/proteome projects of the last 10 years
have identified the spectrum of proteins at
differentstages of thelifecycleinwhichthere
are likely to be many potential new candi-
dates that need to be evaluated [23]. Criteria
or guidelines to assist in the prioritisation of
antigens have been developed (see, for
example, http://www.emvi.org/Portfolio/
EC+Funded+Projects/EURHAVAC). Such
guidelines can be obvious (but not always
followed), for example,i fi ti sp r o p o s e dt h a ta
particularantigenisthetargetofantibodiesit
must be accessible at the appropriate time in
t h el i f ec y c l e .W em u s ta c c e l e r a t et h e
movement of ideas from basic science to the
first step of potential development: funding
for this has often been limited because it falls
into the gap between basic and applied
science.
Clearly, any strategy for vaccine devel-
opment will need to focus equally on the
delivery system to induce the right sort and
level of response and the antigens to
ensure that the response is effective. There
is growing interest in immunisation
by using live and attenuated parasites
[24–26]. Provided that the practical issues
of delivery and regulatory and ethical
issues of safety can be overcome, then
genetic modification of the parasite could
provide immense benefit; for example,
developing an in vitro system for sporozo-
ite replication, developing a parasite
expressing critical antigens normally ex-
pressed at other stages such as expressing
the sexual stage antigen Pfs25 on the
sporozoite surface, or using genetic inac-
tivation techniques [27]. Parasites that
have lost the ability to regulate var gene
expression [28] or blood stage parasites
attenuated by metabolic mutants [26] are
potential vaccine candidates. Even if using
parasites is a feasible approach, it still
needs to be established that a single
vaccine strain has the potential to deliver
the diversity of sequence necessary if
antigen diversity/variation is important.
The Need for Good Assays
There are too few resources to follow an
entirely empirical approach to vaccine
discovery and development. Therefore,
there needs to be a focus on the develop-
ment of assays that may be predictive of
protection in humans. In the absence of a
vaccine that works through a known
mechanism, there is no gold standard to
establish and calibrate in vitro (or in vivo)
assays that are predictive of a protective
immune response. A conundrum is, how is
it possible to do comparative studies of
different vaccines with assays that are not
validated? Recent developments in trans-
genic host and transgenic parasite technol-
ogy [29,30] represent an important
achievement that may help out here, but
may alsoyield some surprises. Forexample,
studies usingPlasmodium berghei expressing P.
falciparum CSP suggest that CSP is not
important in immunity provided by immu-
nisation with attenuated sporozoites [31].
Thisis a surprising findingsince the leading
malaria vaccine candidate, RTS,S, is
comprised of part of CSP in a virus-like
particle and a strong adjuvant. In other
studies, a role for antibody Fc-dependent
mechanisms has been highlighted using
passive immunization with human anti-
body of mice that are transgenic for human
Fc receptors and challenged with a P. berghei
that is transgenic for part of P. falciparum
MSP1 [32]. However, as with other assays,
the relevance to humans still needs to be
established.
PLoS Pathogens | www.plospathogens.org 2 October 2009 | Volume 5 | Issue 10 | e1000638The priorities are to ascertain the basis
of protection against malaria and develop
delivery systems to elicit the right immu-
nological response and memory. These
delivery systems may be attenuated para-
sites, vectored vaccines, or adjuvant and
subunit protein-based. No doubt new and
better antigens will be identified and
prioritised, and combinations will need to
be tested, with different targets and
effector mechanisms at different stages of
the life cycle. All of this will need to be
underpinned by basic biological studies.
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